AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
Phase 4
Completed
- Conditions
- Bipolar DisorderManic DisorderManiaManic StateBipolar Affective Psychosis
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 88
- Registration Number
- NCT00521365
- Locations
- 🇲🇽
Research Site, San Luis Potosi, Mexico
A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 385
- Registration Number
- NCT00520572
- Locations
- 🇸🇰
Research Site, Piestany, Slovakia
A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17
- Registration Number
- NCT00517283
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
Phase 1
Completed
- Conditions
- Malignant Solid Tumors
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00516438
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
Phase 1
Completed
- Conditions
- Ovarian NeoplasmsBRCA1 ProteinBRCA2 Protein
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT00516373
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Diabetic Under 70 (Diabetics Below 70)
Completed
- Conditions
- HyperlipidemiaDiabetesAtherosclerosis
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 685
- Registration Number
- NCT00516204
- Locations
- 🇦🇹
Research Site, Vienna, Austria
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
Phase 1
Completed
- Conditions
- CarboplatinTriple Negative Metastatic Breast CancerAdvanced Ovarian CancerPaclitaxel
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 189
- Registration Number
- NCT00516724
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
Phase 1
Completed
- Conditions
- Melanoma Neoplasms
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00516802
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT00516048
- Locations
- 🇰🇷
Research Site, Suwon City, Korea, Republic of
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic Neoplasms
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 68
- Registration Number
- NCT00515866
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath